Scopolamine - Generic Drug Details

✉ Email this page to a colleague

What are the generic sources for scopolamine and what is the scope of freedom to operate?

Scopolamine is the generic ingredient in two branded drugs marketed by Actavis Labs Ut Inc, Mylan Technologies, Padagis Us, Rhodes Pharms, Riconpharma Llc, Zydus Pharms, and Baxter Hlthcare Corp, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty-one drug master file entries for scopolamine. Ten suppliers are listed for this compound.

Summary for scopolamine

US Patents:	0
Tradenames:	2
Applicants:	7
NDAs:	7
Drug Master File Entries:	21
Finished Product Suppliers / Packagers:	10
Raw Ingredient (Bulk) Api Vendors:	41
Clinical Trials:	80
Patent Applications:	6,653
Drug Prices:	Drug price trends for scopolamine
What excipients (inactive ingredients) are in scopolamine?	scopolamine excipients list
DailyMed Link:	scopolamine at DailyMed

See drug prices for scopolamine

Recent Clinical Trials for scopolamine

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Yale University	Phase 1
Janssen Scientific Affairs, LLC	Phase 1
Dartmouth-Hitchcock Medical Center	Phase 1

See all scopolamine clinical trials

Pharmacology for scopolamine

Drug Class	Anticholinergic
Mechanism of Action	Cholinergic Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for scopolamine

US Patents and Regulatory Information for scopolamine

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan Technologies	SCOPOLAMINE	scopolamine	SYSTEM;TRANSDERMAL	203753-001	Jun 19, 2019	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Zydus Pharms	SCOPOLAMINE	scopolamine	SYSTEM;TRANSDERMAL	217893-001	Aug 29, 2024	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Baxter Hlthcare Corp	TRANSDERM SCOP	scopolamine	SYSTEM;TRANSDERMAL	017874-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Padagis Us	SCOPOLAMINE	scopolamine	SYSTEM;TRANSDERMAL	078830-001	Jan 30, 2015	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for scopolamine

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare Corp	TRANSDERM SCOP	scopolamine	SYSTEM;TRANSDERMAL	017874-001	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Baxter Hlthcare Corp	TRANSDERM SCOP	scopolamine	SYSTEM;TRANSDERMAL	017874-001	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Baxter Hlthcare Corp	TRANSDERM SCOP	scopolamine	SYSTEM;TRANSDERMAL	017874-001	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.